Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation
about
Gastrointestinal adverse effects of varenicline at maintenance dose: a meta-analysisSmoking and chronic obstructive pulmonary disease (COPD). Parallel epidemics of the 21 centuryNerve agent exposure elicits site-specific changes in protein phosphorylation in mouse brainNicotine receptor partial agonists for smoking cessationPharmacological interventions for promoting smoking cessation during pregnancyNicotine receptor partial agonists for smoking cessationPharmacological interventions for promoting smoking cessation during pregnancyNicotine receptor partial agonists for smoking cessationInnate C-H trifluoromethylation of heterocyclesUnravelling the mechanism of action of NS9283, a positive allosteric modulator of (α4)3(β2)2 nicotinic ACh receptorsNicotine receptors and depression: revisiting and revising the cholinergic hypothesisNicotine binding to brain receptors requires a strong cation-pi interactionVarenicline for smoking cessation: a narrative review of efficacy, adverse effects, use in at-risk populations, and adherenceOrthosteric and Allosteric Ligands of Nicotinic Acetylcholine Receptors for Smoking CessationBacoside A: Role in Cigarette Smoking Induced Changes in BrainMolecules and circuits involved in nicotine addiction: The many faces of smokingPreclinical evidence that activation of mesolimbic alpha 6 subunit containing nicotinic acetylcholine receptors supports nicotine addiction phenotypeRational development of addiction pharmacotherapies: successes, failures, and prospectsImprovement of restless legs syndrome by varenicline as antismoking treatmentEnantiopure Cyclopropane-Bearing Pyridyldiazabicyclo[3.3.0]octanes as Selective α4β2-nAChR Ligands.Structural Characterization of Binding Mode of Smoking Cessation Drugs to Nicotinic Acetylcholine Receptors through Study of Ligand Complexes with Acetylcholine-binding ProteinMolecular actions of smoking cessation drugs at 4 2 nicotinic receptors defined in crystal structures of a homologous binding proteinTargeting α4β2 nicotinic acetylcholine receptors in central nervous system disorders: perspectives on positive allosteric modulation as a therapeutic approach.Nicotinic receptor modulation to treat alcohol and drug dependenceEmerging drugs for the treatment of tobacco dependence: 2014 updateThe role of the habenula in drug addiction.An overview of the synthetic routes to the best selling drugs containing 6-membered heterocyclesFunctional probes of drug-receptor interactions implicated by structural studies: Cys-loop receptors provide a fertile testing groundPrescription drugs associated with reports of violence towards othersMechanisms of inhibition and potentiation of α4β2 nicotinic acetylcholine receptors by members of the Ly6 protein familyImpact of physical exercise on substance use disorders: a meta-analysisNicotinic Activity of Arecoline, the Psychoactive Element of "Betel Nuts", Suggests a Basis for Habitual Use and Anti-Inflammatory ActivityVarenicline Effects on Smoking, Cognition, and Psychiatric Symptoms in Schizophrenia: A Double-Blind Randomized TrialVarenicline is a potent partial agonist at α6β2* nicotinic acetylcholine receptors in rat and monkey striatumConductance of P2X4 purinergic receptor is determined by conformational equilibrium in the transmembrane regionnAChR dysfunction as a common substrate for schizophrenia and comorbid nicotine addiction: Current trends and perspectives.Cognitive deficits in schizophrenia: focus on neuronal nicotinic acetylcholine receptors and smoking.Treatment of nicotine addiction: present therapeutic options and pipeline developments.Effects of varenicline and bupropion sustained-release use plus intensive smoking cessation counseling on prolonged abstinence from smoking and on depression, negative affect, and other symptoms of nicotine withdrawalHow can we use our knowledge of alcohol-tobacco interactions to reduce alcohol use?
P2860
Q21254640-BAC8D654-E5DC-45F2-88BF-A548E7700557Q22305613-6EE7C590-8714-4856-AB9D-8A252B086058Q23913649-84225A44-8538-4BB0-8DD3-34D64C7C1AF5Q24185773-4FB817EA-F423-481E-8E5C-F2901B37DFB8Q24186969-B714E348-C8D9-4B2C-A6CF-6946F67FD4B5Q24200322-86A2251A-D7B8-4C9F-961A-7895E64847F3Q24200435-7DA3EF37-AA06-4BB8-AA75-581436F03EE7Q24235456-3B9A4E9D-48B3-4C95-B442-4F9A374EF6D7Q24603689-5361EB3B-7743-4F64-BE99-6165ACBD2F1BQ24634426-A34BD7D3-DC35-428B-9BC5-64B052F9D721Q24634536-077ECD01-C7A3-4531-AF0B-A028979D619FQ24641901-6C5AE0DD-3D37-4B88-BCD0-8E386109632AQ26751374-5CA52EF9-3277-45DA-8618-458FFD96223DQ26774830-C1461A62-9E2C-44B8-BCE7-82FA017298F4Q26786019-837D5747-EC23-471A-9666-DEECEEED308CQ27008063-8F0B1ED3-D628-4271-A040-0FB1E0C34487Q27021772-262D9936-43C8-4138-AE65-E3DADF545775Q27025533-1087903A-F1D3-43D4-9EE7-4C5C6037596DQ27025687-AAD8C706-FC53-4104-A88E-42CC0A283CB8Q27335322-B048A351-C1D1-4CEF-B513-AEDFC176CEC8Q27678875-C3060060-B070-4A6B-A3D5-EF76C8227EC7Q27679259-E9BC8A0F-0DA8-4567-86E8-92C127DF474CQ27693356-CA283F7C-C17E-4E0B-9FDF-F93C198D3A6BQ28087047-AB3023C4-F252-45B2-8CB5-9D82CE471620Q28236453-44BA318C-C7F3-4657-81EA-D76FE8908B34Q28238267-23322953-E6E8-4B9F-8817-5A9180501992Q28301501-67B0483D-87CA-4587-9AB4-80011297CED0Q28307979-57172901-91AE-4CBB-9A9A-4DF208D93DD5Q28476532-CF7D489E-0DFC-42D7-89B9-96CCFB13C5B1Q28509139-9A94A39F-4D77-4E21-807E-8F85BA31E27AQ28543880-5554D6D7-F73C-4AEB-B2A1-4918565342FBQ28550433-8D033FE3-0AAB-48D4-84DD-ABA742824010Q28552053-68C385E5-E726-440D-B5A7-D702782E4B51Q28576280-23684A15-5EB0-4D7E-91F0-A81C326E2760Q28833615-1180AC83-0A07-42C4-BB2F-5FF43A954EC3Q30362464-F78C3C34-0B46-4220-A7AC-6F789E943EB6Q30396291-17AA0EA3-5BEE-4E38-AB2B-F42F14768FDDQ30398847-97C34286-30AC-40EA-8840-EBF8D56CF182Q30433175-EB885B7C-A986-43A6-9EEA-2260F3E696E3Q30441131-DDF509A6-4ECD-45AE-B8EA-4A747E1219E3
P2860
Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation
description
2005 nî lūn-bûn
@nan
2005 թուականի Մայիսին հրատարակուած գիտական յօդուած
@hyw
2005 թվականի մայիսին հրատարակված գիտական հոդված
@hy
2005年の論文
@ja
2005年論文
@yue
2005年論文
@zh-hant
2005年論文
@zh-hk
2005年論文
@zh-mo
2005年論文
@zh-tw
2005年论文
@wuu
name
Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation
@ast
Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation
@en
Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation
@nl
type
label
Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation
@ast
Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation
@en
Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation
@nl
prefLabel
Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation
@ast
Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation
@en
Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation
@nl
P2093
P3181
P356
P1476
Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation
@en
P2093
Alka Shrikhande
Brian T O'Neill
Carol B Fox
Charles C Rovetti
David W Schulz
Eric P Arnold
Eric Schaeffer
F David Tingley
Hans Rollema
James H Heym
P304
P3181
P356
10.1021/JM050069N
P407
P577
2005-05-19T00:00:00Z